1989
NCI's breast cancer clinical alert: rationale and results.
DeVita V, Hubbard S. NCI's breast cancer clinical alert: rationale and results. Resident & Staff Physician 1989, 35: 49-55. PMID: 10303742.Peer-Reviewed Original Research
1985
The current status of NCI trials in Hodgkin’s disease
Young R, Longo D, Glatstein E, Duffey P, Winkler C, Wiernik P, Devita V. The current status of NCI trials in Hodgkin’s disease. Developments In Oncology 1985, 293-298. DOI: 10.1007/978-1-4613-2607-6_30.Peer-Reviewed Original Research
1981
Current results of the screening program at the division of cancer treatment, national cancer institute
Goldin A, Venditti J, Macdonald J, Muggia F, Henney J, Devita V. Current results of the screening program at the division of cancer treatment, national cancer institute. European Journal Of Cancer 1981, 17: 129-142. PMID: 6894902, DOI: 10.1016/0014-2964(81)90027-x.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteScreening programCancer treatmentClinical trialsCancer InstituteHuman tumorsProspective screening programInadequate clinical trialsCategories of drugsActivity of drugsRenal capsuleClinical testingPanel testingScreening panelNew synthetic compoundsClinical interestNew drugsDrugsSubcutaneous modelTreatmentTumorsAntitumor agentsTrialsPotential usefulnessDefinitive answer
1980
The evolution of primary multimodality treatment in resectable breast cancer
Henney J, Devita V. The evolution of primary multimodality treatment in resectable breast cancer. Cancer 1980, 46: 999-1008. PMID: 6994877, DOI: 10.1002/1097-0142(19800815)46:4+<999::aid-cncr2820461325>3.0.co;2-e.Peer-Reviewed Original ResearchConceptsDisease-free intervalPremenopausal womenClinical trialsBreast cancerProspective randomized clinical trialsStage II breast cancerAdjuvant therapy studiesResectable breast cancerRandomized clinical trialsNational Cancer InstitutePositive resultsPostmenopausal womenMultimodality treatmentPostoperative periodPrognostic factorsNational mortalityClinical dataEstrogen receptorDrug doseCancer InstituteStage IClinical researchPatientsTherapy studiesTrials
1979
Advanced Ovarian Adenocarcinoma A Prospective Clinical Trial of Melphalan (L-PAM) Versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, Devita V. Advanced Ovarian Adenocarcinoma A Prospective Clinical Trial of Melphalan (L-PAM) Versus Combination Chemotherapy. Obstetrical & Gynecological Survey 1979, 34: 414. DOI: 10.1097/00006254-197905000-00027.Peer-Reviewed Original Research
1978
Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, DeVita V. Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy. New England Journal Of Medicine 1978, 299: 1261-1266. PMID: 101843, DOI: 10.1056/nejm197812072992301.Peer-Reviewed Original ResearchConceptsAdvanced ovarian adenocarcinomaFour-drug combinationOverall response rateOvarian adenocarcinomaComplete remissionMedian survivalResidual diseaseResponse rateHigher overall response rateExtensive residual diseaseFour-drug regimenProspective clinical trialsLonger median survivalMinimal residual diseaseAdvanced diseaseCombination chemotherapyClinical trialsSevere toxicityMelphalanPatientsAdenocarcinomaDiseaseRemissionTrialsSurvival
1976
Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine.
Young R, DeVita V. Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine. National Cancer Institute Monograph 1976, 43: 193-200. PMID: 1087955.Peer-Reviewed Original ResearchConceptsPyrimethamine-sulfadiazinePneumocystis pneumoniaPentamidine isethionateClinical trialsPneumocystis carinii pneumoniaManagement of patientsSeverely ill patientsRandomized clinical trialsCarinii pneumoniaLocal toxicityRegimensIll patientsPatientsComplete recoveryPneumoniaPneumocystisIsethionateComparative toxicityTrialsPentamidineToxicity
1975
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.
Young R, Chabner B, Hubbard S, Canellos G, DeVita V. Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma. National Cancer Institute Monograph 1975, 42: 145-8. PMID: 825777.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaOvarian carcinomaHigher overall response rateOral alkylating agentTrials of chemotherapyOverall response ratePAM therapyNational Cancer InstituteIntravenous cyclophosphamideSystemic chemotherapyRemission rateCombination therapyProspective trialsHigh-doseTherapeutic efficacyConventional treatmentResponse rateCancer InstituteChemotherapyAlkylating agentsCarcinomaTherapyTrialsCyclophosphamideMelphalanTherapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy.
Canellos G, DeVita V, Young R, Chabner B, Schein P, Johnson R. Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy. British Journal Of Cancer. Supplement 1975, 2: 474-80. PMID: 1101933, PMCID: PMC2149565.Peer-Reviewed Original ResearchCombination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer
Devita V, Young R, Canellos G. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 1975, 35: 98-110. PMID: 162854, DOI: 10.1002/1097-0142(197501)35:1<98::aid-cncr2820350115>3.0.co;2-b.Peer-Reviewed Original ResearchMeSH KeywordsAdenoma, Islet CellAlkylating AgentsAntineoplastic AgentsBinding, CompetitiveBreast NeoplasmsBurkitt LymphomaChoriocarcinomaCyclophosphamideDrug ResistanceDrug Therapy, CombinationFemaleHodgkin DiseaseHumansLeukemia, LymphoidNeoplasm MetastasisNeoplasmsOvarian NeoplasmsPancreatic NeoplasmsPregnancy
1974
The design of clinical trials in the therapy of ovarian carcinoma
Young R, DeVita V. The design of clinical trials in the therapy of ovarian carcinoma. American Journal Of Obstetrics And Gynecology 1974, 120: 1012-1024. PMID: 4432892, DOI: 10.1016/0002-9378(74)90143-4.Peer-Reviewed Original ResearchConceptsOvarian carcinomaClinical trialsProspective randomized clinical trialsSurvival of patientsCombined modality approachRandomized clinical trialsPrognostic factorsStandardized stagingModality approachTherapySuch trialsCarcinomaMajor causeTrialsPatientsBase lineSurvivalChemotherapyRadiotherapyStagingWomenBCG Vaccine Treatment of Hodgkin Disease
DeVita V. BCG Vaccine Treatment of Hodgkin Disease. JAMA 1974, 228: 28-28. PMID: 4406143, DOI: 10.1001/jama.1974.03230260022015.Peer-Reviewed Original Research
1973
Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man
Sponzo R, Devita V, Oliverio V. Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man. Cancer 1973, 31: 1154-1159. PMID: 4705152, DOI: 10.1002/1097-0142(197305)31:5<1154::aid-cncr2820310517>3.0.co;2-b.Peer-Reviewed Original Research
1972
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Bagley C, Canellos G, Young R, Gallelli J, Devita V. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemotherapy Reports 1972, 56: 387-91. PMID: 19051499.Peer-Reviewed Original ResearchConceptsClinical trialsDose-limiting toxic effectPhase II trialBone marrow toxicityConsecutive daily injectionsTime of onsetDegree of severitySevere nauseaII trialObjective responseDaily injectionsMarrow toxicityPatientsTrialsToxic effectsToxicityNauseaVomitingPainLymphomaMelanomaTumorsLymphosarcomaAdministrationDose
1971
Studies on the Anti-Tumor Action of Poly I: Poly C
Levy H, Adamson R, Carbone P, DeVita V, Gazdar A, Rhim J, Weinstein A, Riley F. Studies on the Anti-Tumor Action of Poly I: Poly C. 1971, 55-65. DOI: 10.1007/978-3-642-85772-0_5.Peer-Reviewed Original Research